Parabilis Medicines, Inc.
Parabilis Medicines, Inc.
Your view on PBLS
Overview
What the company does, where it operates, and who runs it.
About Parabilis Medicines, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mathai Mammen
- Headquarters
- 30 Acorn Park Dr, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Mathai Mammen
- Headquarters
- 30 Acorn Park Dr, Cambridge, MA, US
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L.
Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Parabilis Medicines, Inc. from FRC's valuation model, read against the market price. PBLS last traded at $27.69; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Parabilis Medicines, Inc.. Starting points for Parabilis Medicines, Inc.: EPS -$1.43, beta 5.03 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Parabilis Medicines, Inc.. Parabilis Medicines, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Parabilis Medicines, Inc.. Trailing twelve-month EPS for Parabilis Medicines, Inc. stands at -$1.43. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$40.00
Median
$40.00
High
$40.00
Average target · 1 new target in the last month, average $40.00
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.38 | -$0.39 | -$2.60 | -$1.78 |
| Low estimate | -$0.38 | -$0.39 | -$3.09 | -$2.00 |
| High estimate | -$0.38 | -$0.39 | -$2.10 | -$1.55 |
| No. of analysts | 2 | 1 | 3 | 3 |
| Year-ago EPS | — | — | — | — |
| Growth | — | — | — | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $750000.00 | $1.75M | $1.65M | $9.00M |
| Low estimate | $750000.00 | $1.75M | $1.65M | $9.00M |
| High estimate | $750000.00 | $1.75M | $1.65M | $9.00M |
| No. of analysts | 2 | 1 | 3 | 3 |
| Year-ago revenue | — | — | — | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Parabilis Medicines, Inc.. Parabilis Medicines, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Parabilis Medicines, Inc. valued side by side against its closest peers. Parabilis Medicines, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Parabilis Medicines, Inc., and how their positions are changing. At a $3.38B market value, institutional positions materially move Parabilis Medicines, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Parabilis Medicines, Inc. executives and directors. Shares of Parabilis Medicines, Inc. have traded between $24.51 and $36.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Parabilis Medicines, Inc.. Coverage tracks Parabilis Medicines, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Parabilis Medicines, Inc.